驱动力(838275) - 2022 Q4 - 年度财报(更正)

Financial Performance - The company's revenue for 2022 was corrected to ¥97,072.53 million, a decrease of 28.62% compared to 2021[6]. - The net profit attributable to shareholders for 2022 was corrected to ¥17,399.34 million, reflecting a decrease of 56.52% year-over-year[10]. - The gross profit margin for 2022 was adjusted to 30.56%, down from 43.98% in 2021[6]. - The basic earnings per share for 2022 was corrected to ¥0.11, a decline of 56% compared to ¥0.25 in 2021[5]. - The overall operating profit margin was reported at 12.4%, down from 31.3% in the previous year[19]. - The operating profit for the reporting period was 19.19 million, a decrease of 55.43% compared to 2021, primarily due to a smaller increase in main business income compared to the increase in operating costs[24]. - The net profit for the reporting period was 17.38 million, a decrease of 56.56% compared to 2021, influenced by multiple factors[24]. - The company reported a net profit margin impacted by increased R&D expenses and operational costs[58]. - Total operating revenue for 2022 was 97,072,539, a decrease of 28.5% compared to 135,985,501 in 2021[60]. - Net profit for 2022 was 17,382,063, representing a decline of 56.6% from 40,017,018 in 2021[62]. Cash Flow - The net cash flow from operating activities for 2022 was ¥54,469.48 million, an increase of 112% from ¥25,658.46 million in 2021[8]. - The net cash flow from operating activities was 54,469.5 million, an increase of 112.29% compared to the previous year, driven by higher sales cash ratios[35]. - The net cash flow from investing activities was -21,838.7 million, an increase of 68.51% year-on-year, mainly due to reduced fixed asset investments[35]. - The net cash flow from financing activities was -49,349.2 million, a decrease of 245.05% compared to the previous year, attributed to the absence of external financing in 2022[35]. Operating Costs and Expenses - Operating costs amounted to 67,410,728 yuan, reflecting a decrease of 11.51% from 76,174,676 yuan in the previous year[19]. - Sales expenses were 10,897,595 yuan, a reduction of 15.18% compared to 12,847,418 yuan in the previous year[19]. - The operating cost for the reporting period was 67.18 million, a decrease of 11.58% compared to 2021, mainly due to reduced sales volume of blood products[25]. - Research and development expenses increased by 19.23% to 4,749,646 yuan from 3,983,697 yuan in the previous year[19]. Revenue Sources - The revenue from hematopoietic products was 84,102.3 million, a decrease of 8.55% compared to the same period in 2021[32]. - The revenue from other products was 12,970.2 million, a decrease of 70.54% year-on-year, primarily due to a reduction in various feed materials and technical service fees[31]. - Revenue from blood products was 79,906,522.33, down from 89,420,301.90 in the previous period[64]. - Revenue from stress-resistant and appetite-inducing products was 4,195,808.87, an increase from 2,543,664.50 in the previous period[64]. - Revenue from concentrated feed and additives was 8,702,552.93, down from 30,976,376.37 in the previous period[64]. Audit and Compliance - The company identified revenue recognition as a key audit matter due to the inherent risk of management manipulating revenue recognition timing[48]. - The company has implemented significant audit procedures to evaluate the effectiveness of internal controls related to revenue recognition[49]. - The company's revenue recognition policy aligns with accounting standards, ensuring compliance[55]. - The company’s management has been proactive in addressing potential risks associated with revenue recognition practices[48]. Subsidiaries and Investments - The company has four wholly-owned subsidiaries, one controlling subsidiary, and one associated company as of December 31, 2022[42]. - Guangzhou Sanhang Biotechnology Co., Ltd. generated revenue of 3.76 million yuan and a net profit of 0.55 million yuan during the reporting period[42]. - Guangzhou Sanhang Feed Co., Ltd. achieved revenue of 11.83 million yuan and a net profit of 0.87 million yuan[45]. - Guangdong Sanhang Biotechnology Co., Ltd. reported revenue of 37.09 million yuan and a net profit of 0.31 million yuan[45]. - Guangzhou Saitao Flower Biotechnology Co., Ltd. generated revenue of 2.56 million yuan and a net profit of 1.37 million yuan[45]. - Guangdong Sanhang Blood Feed Co., Ltd. reported a net loss of 0.035 million yuan during the reporting period[43]. - Guangdong Xinnandu Feed Technology Co., Ltd. achieved revenue of 55.96 million yuan and a net profit of 5.46 million yuan[45]. Management Commentary - The company expressed apologies for any inconvenience caused by the corrections made in the financial report[65]. - The company plans to expand its market presence and enhance product offerings through new technology development and strategic partnerships[30].